Related Experiment Videos
A HER 1-2 punch: dual EGFR targeting deals resistance a deadly blow
Don L Gibbons1, Lauren Averett Byers2
1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Summary:
Ten years after the approval of erlotinib, EGFR inhibitor resistance remains a major clinical challenge. The translation of afatinib plus cetuximab into the clinic provides a promising new option for the treatment of patients with EGFR-mutated lung cancer.
Insights
Epidermal growth factor receptor (EGFR) inhibitor resistance is a significant clinical hurdle. Afatinib combined with cetuximab offers a new therapeutic avenue for EGFR-mutated lung cancer patients.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, has been used for over a decade.
- Resistance to EGFR inhibitors presents a major clinical challenge in lung cancer treatment.
Purpose of the Study:
- To evaluate the efficacy of afatinib plus cetuximab in EGFR-mutated lung cancer.
- To address the unmet need for effective therapies in the face of EGFR inhibitor resistance.
Main Methods:
- Clinical trial design (details not provided in abstract).
- Patient selection based on EGFR mutation status.
- Treatment with afatinib and cetuximab.
Main Results:
- Afatinib plus cetuximab demonstrates clinical utility.
- This combination offers a promising treatment option.
Conclusions:
- EGFR inhibitor resistance remains a significant clinical challenge ten years post-erlotinib approval.
- Afatinib plus cetuximab represents a promising new therapeutic strategy for patients with EGFR-mutated lung cancer.